Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Jul 18;17(1):324.
doi: 10.1186/s13063-016-1449-3.

A randomised controlled trial of calcium channel blockade (CCB) with Amlodipine For the treatment oF subcortical ischaEmic vasCular demenTia (AFFECT): study protocol

Caroline Greenan  1 , Lynn Murphy  1 , Ly-Mee Yu  2 , Patrick G Kehoe  3 , Elizabeth Coulthard  3 , Philip Bath  4 , Robert Stewart  5 , Rob Jones  6 , Anne Corbett  7 , Alan Thomas  8 , Peter Connelly  9 , Frank Arrojo  10 , Rachel Canning  10 , Sylvia Wallach  10 , Catherine Henderson  11 , Bernadette McGuinness  12 , Mike O'Sullivan  13 , Clive Holmes  14 , Martin Knapp  11 , Clive Ballard  15 , Peter Passmore  16 ; AFFECT Investigators
Collaborators, Affiliations
Clinical Trial

A randomised controlled trial of calcium channel blockade (CCB) with Amlodipine For the treatment oF subcortical ischaEmic vasCular demenTia (AFFECT): study protocol

Caroline Greenan et al. Trials. .

Abstract

Background: Vascular dementia is the second most common cause of dementia affecting over seven million people worldwide, yet there are no licensed treatments. There is an urgent need for a clinical trial in this patient group. Subcortical ischaemic vascular dementia is the most common variant of vascular dementia. This randomised trial will investigate whether use of calcium channel blockade with amlodipine, a commonly used agent, can provide the first evidence-based pharmacological treatment for subcortical ischaemic vascular dementia.

Methods/design: This is a randomised controlled trial of calcium channel blockade with Amlodipine For the treatment oF subcortical ischaEmic vasCular demenTia (AFFECT) to test the hypothesis that treatment with amlodipine can improve outcomes for these patients in a phase IIb, multi-centre, double-blind, placebo-controlled randomised trial. The primary outcome is the change from baseline to 12 months in the Vascular Dementia Assessment Scale cognitive subscale (VADAS-cog). Secondary outcomes include cognitive function, executive function, clinical global impression of change, change in blood pressure, quantitative evaluation of lesion accrual based on magnetic resonance imaging (MRI), health-related quality of life, activities of daily living, non-cognitive dementia symptoms, care-giver burden and care-giver health-related quality of life, cost-effectiveness and institutionalisation. A total of 588 patients will be randomised in a 1:1 ratio to either amlodipine or placebo, recruited from sites across the UK and enrolled in the trial for 104 weeks.

Discussion: There are no treatments licensed for vascular dementia. The most common subtype is subcortical ischaemic vascular dementia (SIVD). This study is designed to investigate whether amlodipine can produce benefits compared to placebo in established SIVD. It is estimated that the numbers of people with VaD and SIVD will increase globally in the future and the results of this study should inform important treatment decisions.

Trial registration: Current Controlled Trials ISRCTN31208535 . Registered on 7 March 2014.

Keywords: Amlodipine; Calcium channel blockade; Cognitive outcome; Subcortical ischaemic vascular dementia; Vascular dementia.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Study schematic for the AFFECT trial
See this image and copyright information in PMC

References

    1. Alzheimer’s Disease International. World Alzheimer’s Report 2010. The Global Economic Impact of Dementia. London: Alzheimer’s Disease International; 2010.
    1. Malouf R, Birks J. Donepezil for vascular cognitive impairment. Cochrane Database Syst Rev. 2004;1:CD004395. - PubMed
    1. Román GC. Vascular dementia may be the most common form of dementia in the elderly. J Neurol Sci. 2002;203–204:7–10. doi: 10.1016/S0022-510X(02)00252-6. - DOI - PubMed
    1. O’Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, Bowler JV, Ballard C, DeCarli C, Gorelick PB, Rockwood K, Burns A, Gauthier S, DeKosky ST. Vascular cognitive impairment. Lancet Neurol. 2003;2:89–98. - PubMed
    1. Tarvonen-Schröder S, Röyttä M, Räihä I, Kurki T, Rajala T, Sourander L. Clinical features of leuko-araiosis. J Neurol Neurosurg Psychiatry. 1996;60:431–6. doi: 10.1136/jnnp.60.4.431. - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data